MRKbenzinga

FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors

Summary

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 14, 2025 by benzinga

    FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors | MRK Stock News | Candlesense